The Swings and Roundabouts of Randomized Controlled Studies in Wound Healing

The International Journal of Lower Extremity Wounds

Volumn 3, Issue 1, 2004, Pages 4-6

  Margolis, David J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84993661101     PISSN: 15347346     EISSN: 15526941     Source Type: Journal    
DOI: 10.1177/153473460431002     Document Type: Editorial

References (33)

1. Margolis DJ, Bilker W, Santanna J, Baumgarten M. Venous leg ulcer: incidence and prevalence in the elderly. J Am Acad Dermatol 2002; 46: 381-386.
2. Callam MJ. Epidemiology of varicose veins. Br J Surg 1994; 81: 167-173.
3. Dale JJ, Callam MJ, Ruckley CV, Harper DR, Berrey PN. Chronic ulcers of the leg: a study of prevalence in a Scottish community. Health Bull 1983; 41: 310-314.
4. Hallbook T. Leg ulcer epidemiology. Acta Chir Scand 1988; 544: 17-20.
5. Ruckley CV. Socioeconomic impact of chronic venous insufficiency and leg ulcers. Angiology 1997; 48: 67-69.
6. Phillips TJ. Chronic cutaneous ulcers: etiology and epidemiology. J Invest Dermatol 1994; 102: S38-S41.
7. Kantor J, Margolis DJ. Management of leg ulcers. Semin Cutaneous Med Surg 2003; 22: 212-221.
8. Hing E. Characteristics of elderly home health patients: preliminary data from the 1992 national home and hospice care survey. Advance Data 1994; 247: 1-11.
9. Woodall RD. Tissue viability. Living with leg ulcers: a patient’s personal experience. Nurs Stand 1996; 10: 52.
10. Phillips T, Stanton B, Provan A, Lew R. A study of the impact of leg ulcers on quality of life: finanicial, social, and psychologic implications. J Am Acad Dermatol 1994; 31: 49-53.
11. Callam MJ, Ruckley CV, Harper DR, Dale JJ. Chronic ulceration of the leg: extent of the problem and provision of care. BMJ 1985; 290: 1855-1856.
12. Phillips TJ. Chronic cutaneous ulcers: etiology and epidemiology [review]. J Invest Dermatol 1994; 102: 38S-41S.
13. Falanga V, Eaglstein WH. A therapeutic approach to venous ulcers. J Am Acad Dermatol 1986; 14: 777-784.
14. Martin P. Wound healing—aiming for perfect skin regeneration. Science 1997; 276: 75-81.
15. Clark RAF. Wound repair: overview and general considerations. In: Clark RAF, editor. The molecular and cellular biology of wound repair. 2nd ed. New York: Plenum; 1996. p. 3-50.
16. Falanga V. Chronic wounds: pathophysiologic and experimental considerations. J Invest Dermatol 1993; 100: 721-725.
17. Weingarten MS. State-of-the-art treatment of chronic venous disease. Clin Infect Dis 2001; 32: 949-954.
18. Falanga V, Sabolinski M. A bilayered living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regeneration 1999; 7: 201-207.
19. Gentzkow GD, Iwasaki SD, Hershon KS, et al. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996; 19: 350-354.
20. Kantor J, Margolis DJ. Expected healing rates for chronic wounds. Wounds 2000; 12: 155-158.
21. Steed DL, Donohoe D, Webster MW, Lindsley L. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group. J Am Coll Surg 1996; 183: 61-64.
22. Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J Vasc Surg 1995; 21: 71-78.
23. Bennett SP, Griffiths GD, Schor AM, Leese GP, Schor SL. Growth factors in the treatment of diabetic foot ulcers. Br J Surg 2003; 90: 133-146.
24. Veves A, Falanga V, Armstrong DG, Sabolinski ML. The Apligraf Diabetic Foot Ulcer Study. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001; 24: 290-295.
25. Falanga V, Margolis D, Alvarez O, et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Human Skin Equivalent Investigators Group. Arch Dermatol 1998; 134: 293-300.
26. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropahtic diabetic ulcers. Diabetes Care 1998; 21: 822-827.
27. Badiavas EV, Falanga V. Treatment of chronic wounds with bone marrow-derived cells. Arch Dermatol 2003; 139: 510-516.
28. Tateishi-Yuyama E, Matsubara H, Murojara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologus transplantation of bone-marrow cells: a pilot study and a randomized controlled trial. Lancet 2002; 360: 427-435.
29. Bergstrom N, Demuth P, Braden B. A clinical trial of the Braden scale for predicting pressure sore risk. Nurs Clin North Am 1987; 22: 417-428.
30. Gelfand JM, Hofstad O, Margolis DJ. Surrogate endpoints for treatment of venous leg ulcers. J Invest Dermatol 2002; 119: 1420-1425.
31. Margolis DJ, Taylor LA, Hofstad O, Berlin JA. Diabetic neuropathic foot ulcers: predicting which ones will not heal. Am J Med 2003; 115: 627-631.
32. Margolis DJ, Gelfand JM, Hofstad O, Berlin JA. Surrogate endpoints for the treatment of diabetic neuropathic foot ulcers. Diabetes Care 2003; 26: 1696-1700.
33. Margolis DJ, Taylor LA, Hofstad O, Berlin JA. The accuracy of venous leg ulcer prognostic models in a wound care system. Wound Repair Regen. In press.